Five New Hospitals Order ValiMed™ MVS by CDEX to Protect Patients
TUCSON, AZ–(Marketwire – April 14, 2010) – CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces it has received five orders for ValiMed™ Medication Validation Systems (MVS) from new hospital clients in states including Illinois, Pennsylvania, Florida, and Colorado. Studies worldwide continue to show high numbers of mistakes in the compounding of high-risk medications resulting in substantial harm to patients and economic loss to hospitals. ValiMed MVS is used to validate the compounding of high-risk liquid medications in a pharmacy setting and also as a verification and trending program to identify and reduce the diversion of return narcotics in hospitals and other healthcare facilities.
“The new orders for ValiMed™ MVS Units demonstrate the traction we are gaining with the new marketing direction that I introduced at CDEX last year,” said Greg Firmbach, CDEX President. “I have expanded the sales force in the wake of these new orders and expect the momentum to grow over this year. We are looking at additional sales channels to take advantage of the loosening medical budgets and the growing recognition that human errors in the compounding of high risk medications are harming patients — directors of pharmacy know this to be the case and ValiMed™ MVS provides another arrow in their quiver of tools to protect patients, all for about $2.70 per test.”
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ MVS product line provides life-saving validation of high-risk medications and helps prevent diversion of returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings.
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.